Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Satoshi Kawashima
Institution:
National Cancer Center Hospital
Observed institution:
National Cancer Center Hospital
ORCID:
0000-0002-5289-5518
Observed ORCID:
0000-0002-5289-5518
OpenAlex ID:
A5037522641
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial
2023
·
Tadaaki Nishikawa
, Kosei Hasegawa
, et al.
·
Journal of Clinical Oncology
·
132
PDF
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial
2026
·
Shinichi Makita
, Junji Koya
, et al.
·
Blood Advances
·
1
The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial).
2025
·
Dai Ogata
, Eiji Nakano
, et al.
·
Journal of Clinical Oncology
Perfume trial: Phase II trial of binimetinib in patients with BRAF fusion-positive low-grade glioma or pancreatic cancer.
2025
·
Tomoyuki Satake
, Makoto Ohno
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
4
Citation count:
138
H-index:
1
I10-index:
1
Year
Topic
Type